It is worth noting that CDDP treatment upregulates DNA damage repair-related genes, such as ERCC1, XPA, RAD23B, and MSH2. In our study, Galectin-1 was newly confirmed as the downstream target of c-Jun-ATF2 in liver cancer. This evidence concerns the gene MSH2 and liver cancer.